Treatment Options for Renal Cell Carcinoma: Mechanisms and Outcomes
نویسندگان
چکیده
Renal Cell Carcinoma (RCC), cancer of the tubules kidneys, has historically been one most difficult cancers to treat due its ability remain hidden in body for longer than other and tendency resist traditional forms chemotherapy radiation therapy. However, both nontraditional treatments RCC have seen significant biomedical advancements clinical instances use recent years. In this review, we analyze five RCC: Nephrectomy, Immunotherapy, Anti-Angiogenesis, Chemotherapy, Radiation Therapy, providing background on their mechanisms outcomes. Through our review studies outcomes, reaffirm existing thought that nephrectomy remains effective treatment RCC, while therapy are generally less not recommended own. Immunotherapy anti-angiogenic shown be modern healthcare landscape show great potential future as techniques better developed optimized.
منابع مشابه
Current and Future Treatment Options for Metastatic Renal Cell Carcinoma
Context: Metastatic renal cell carcinoma (mRCC) is associated with poor survival, and until recently, treatment options have been very limited. However, the advent of targeted therapies has radically improved the outlook for patients with mRCC. Objective: This review describes current treatment options for mRCC and summarizes the data on efficacy and safety of approved and newly emerging target...
متن کاملNew treatment options for metastatic renal cell carcinoma
During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosinekinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin pathway (temsirolimus, everolimus) were since then pro...
متن کاملCurrent Treatment Options for Disseminated Renal Cell Carcinoma
Renal cell carcinoma (RCC) is a common urologic tumor and accounts for about 3% of all human malignancies; its incidence has increased steadily in recent decades. Because 40–50% of all RCC patients present with or will develop metastasis, the annual mortality-to-incidence ratio with RCC is significantly higher compared with other urologic malignancies. Only recently, the discovery of specific g...
متن کاملTreatment options in renal cell carcinoma: past, present and future.
Cytokine therapies have been the standard of care in metastatic renal cell carcinoma (RCC). However, these agents only provide clinical benefit to a small subset of patients and are associated with significant toxicity. A better understanding of the molecular biology of RCC has identified the vascular endothelial growth factor (VEGF) and platelet-derived growth factor signalling pathways as rat...
متن کاملTreatment options for renal cell carcinoma in renal allografts: a case series from a single institution.
Renal cell carcinoma (RCC) is more common in renal transplant and dialysis patients than the general population. However, RCC in transplanted kidneys is rare, and treatment has previously consisted of nephrectomy with a return to dialysis. There has been recent interest in nephron-sparing procedures as a treatment option for RCC in allograft kidneys in an effort to retain allograft function. Fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of urologic oncology
سال: 2023
ISSN: ['2617-7765', '2617-7773']
DOI: https://doi.org/10.32948/auo.2023.06.28